Retention of Platinum Sensitivity till Late Stages of Tumour Progression May Imply Improved Prognosis of Oesophageal and Gastric Cancers

作者：Hingorani Mohan^*; Dixit Sanjay; Roy Rajarshi; Maraveyas Anthony

来源：Oncology Research and Treatment, 2015, 38(1-2): 28-34.

DOI：10.1159/000371506

• Chemotherapy
• Oesophageal cancer
• Gastric cancer
• Palliative
• Second-line treatment

Background: We report on the outcomes of patients with metastatic oesophago-gastric (OG) cancer progressing after first-line platinum-based chemotherapy (PBCT) who received a re-challenge schedule of PBCT (r-PBCT) as second-line therapy. Patients and Methods: Patients with metastatic OG cancer treated with first-line PBCT (n = 138) between January 2009 and June 2013 were selected for the purpose of the study. Treatmentrelated outcomes were assessed including response rates, progression-free survival (PFS) and overall survival (OS). Results: 43 (32%) patients progressed (group A: platinum resistant (PR)) and 95 (68%) patients showed a response (group B: platinum sensitive (PS)) or had stable disease after first-line PBCT. Approximately 20% (9/43) of the patients in group A received second-line chemotherapy compared to 50% (38/80) in group B. Most patients (39/47) received r-PBCT, and the remaining patients (8/47) were treated with irinotecan-based chemotherapy. More than 50% (20/39) of the patients achieved disease control, with median PFS and OS of 3 months (95% confidence interval (Cl) = 2.0-4.0 months) and 5.7 months (95% Cl = 4.7-6.7 months) after commencement of r-PBCT. The actuarial median OS of patients responding to second-line or second and third lines of r-PBCT was 26.7 and 30.1 months, respectively. Conclusion: In platinum responders, r-PBCT appears to be an appropriate second-line option with survival outcomes comparable to those of other agents.

• 出版日期2015-2